; and (3) describing research investments by type, funded entities, and level of investment. (j) Evaluation report (1) In general Not later than one year after the date of the enactment of this subsection, and every 5 years thereafter, the Comptroller General of the United States shall submit to the Administrator of the United States Agency for International Development and the appropriate congressional committees a report that evaluates the performance and impact on tuberculosis prevention, diagnosis, treatment, and care efforts that are supported by United States bilateral assistance funding, including recommendations for improving such programs. (2) Form The report required under paragraph (1) shall be submitted in unclassified form, but may contain a classified annex if necessary. (3) Public availability The Comptroller General shall publish the unclassified portion of the report required under paragraph (1) on a publicly available website of the Government Accountability Office. (k) Definitions In this section: (1) Appropriate congressional committees The term appropriate congressional committees means the Committee on Foreign Relations of the Senate and the Committee on Foreign Affairs of the House of Representatives. (2) Global Alliance for Tuberculosis Drug Development The term Global Alliance for Tuberculosis Drug Development means the public-private partnership that bring together leaders in health, science, philanthropy, and private industry to devise new approaches to tuberculosis. (3) Global Tuberculosis Drug Facility The term Global Tuberculosis Drug Facility (GDF) means the initiative of the Stop Tuberculosis Partnership to increase access to the most advanced, affordable, quality-assured tuberculosis drugs and diagnostics. (4) End TB Strategy The term End TB Strategy means the strategy to eliminate tuberculosis approved by the World Health Assembly in May 2014, which is described in The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. (5) Stop